Piper Sandler Maintains Overweight Rating on Boston Scientific Corp (BSX) Following Positive Study Results
Piper Sandler has reaffirmed its Overweight rating on Boston Scientific Corp (NYSE:BSX) following the release of positive results from the Champion-AF study on the Watchman heart implant. The firm expects Watchman sales to grow 20% annually, contributing 200 basis points to Boston Scientific’s revenue growth. Boston Scientific reported strong 2025 financial results, with net sales of $20 billion and adjusted EPS of $3.06.
Tickers: $BSX
Topics: analyst outlook medical devices sales growth stock rating Watchman implant